Company / Operating Income
SANGAMO THERAPEUTICS, INC Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$121.2M
FY2025
5-year range
-$274.0M / -$104.0M
FY2021-FY2025
Trend
-16.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has fluctuated over the past 10 years, ranging from -$274M in FY2023 to -$56M in FY2017.
Based on SEC 10-K filings.
-$121M in FY2025.
Improved from -$274M to -$121M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income decreased 16.6% year-over-year.
- Peak operating income was recorded in FY2017.
- Lowest operating income in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -28.87 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$121.2M | -16.6% |
| FY2024 | -$104.0M | +62.1% |
| FY2023 | -$274.0M | -36.1% |
| FY2022 | -$201.3M | -9.8% |
| FY2021 | -$183.3M | -41.5% |
| FY2020 | -$129.6M | -23.2% |
| FY2019 | -$105.2M | -36.3% |
| FY2018 | -$77.2M | -36.9% |
| FY2017 | -$56.4M | +22.3% |
| FY2016 | -$72.6M | -54.9% |